The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 152.50
Bid: 150.00
Ask: 155.00
Change: -5.00 (-3.17%)
Spread: 5.00 (3.333%)
Open: 157.50
High: 157.50
Low: 152.50
Prev. Close: 157.50
ITX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

13 Sep 2016 11:34

RNS Number : 6915J
Revolymer PLC
13 September 2016
 

 

13 September 2016

Revolymer plc ("Revolymer" or the "Company")

Revolymer appoints non-executive director

 

Revolymer (AIM: REVO) is pleased to announce the appointment of Dr James Joseph Barber as a non executive director with effect from 12 September 2016, representing the interests of the previous shareholders of Itaconix Corporation as their Revolymer board nominee, a right conveyed under the merger agreement between Itaconix Corporation and the Company.

Since 2007, Dr Barber has run his own business consultancy practice, Barber Advisors LLC, and has served as an advisor and a director for a number of firms. Prior to this, Dr. Barber served as President and CEO of Metabolix, Inc. from January 2000 to May 2007. During this period, he led the transformation of Metabolix from a research boutique to a world renowned, highly regarded leader in "clean tech" and industrial biotechnology, building the company into a multi-disciplinary, industry leading, publicly traded enterprise with a market cap of over $500m. He negotiated a highly attractive joint venture arrangement with Archer Daniels Midland for commercialising Metabolix's first product platform, Mirel natural plastics, and took the company public on NASDAQ in November 2006.

Prior to joining Metabolix Inc., Dr Barber served as Global Business Director for the Organometallics and Catalysts business of Albemarle Corporation, with global P&L responsibility for a $100m+ business, and as Representative Director of Nippon Aluminum Alkyls, a joint venture Company between Albemarle Corporation and Mitsui Chemicals, Inc. During his tenure with Albemarle Corporation, he led the development and implementation of strategies that resulted in the strong growth of its polymer catalyst business, including its emerging single-site/metallocene catalyst business.

Prior to his position with Albemarle Corporation, Dr. Barber served as Director, Business Development with Ethyl Corporation, with responsibility for acquisitions and managing Ethyl Corporation's venture capital activities; as President of Geltech, Inc., a venture capital backed company focused in the area of precision moulded micro optics; and as Chief Operating Officer of Hyperion Catalysis International, a pioneering developer and producer of carbon nanofibers.

Dr. Barber received the American Chemical Society's Henry F. Whalen, Jr. award for Business Development in September 2003. He has a BS degree in Chemistry from Rensselaer Polytechnic Institute and a PhD in Organic Chemistry from the Massachusetts Institute of Technology. He serves on the Advancement Council of the College of Polymer Science and Polymer Engineering at the University of Akron, and as a non executive director of Graham Corporation and Nanocomp Technologies, Inc.

Dr Barber commented:

"I am excited to have this opportunity to assist Revolymer through the next phase of its development as it seeks to deliver on its vision of being a leader in functional polymers that manage the interface between different surfaces and phases to improve the safety, performance or sustainability of its customers' products, and I look forward to working with the board, management and investors."

Dr Bryan Dobson, Chairman of Revolymer plc, commented:

"We are very pleased to have appointed Dr Jim Barber to the board of Revolymer as a non-executive director. He has a balance of relevant technical expertise and business management experience, and I am sure will be instrumental in helping shape the future of Revolymer's business."

Additional Information

In accordance with the AIM Rules for Companies, the following information required to be disclosed in relation to Dr Jim Barber is set out below. Other than this information, there is no further information required to be disclosed under paragraph (g) of Schedule Two of the AIM Rules for Companies.

Full name and age: Dr James ("Jim") Joseph Barber, aged 63

Current beneficial shareholding in the Company: nil

Directorships:

Current

Previous (previous 5 years)

Nanocomp Technologies Inc.

Segetis Inc.

Graham Corporation

Itaconix Corporation

Barber Advisors LLC

Agrivida Inc.

Allylix Inc.

 

Dr Barber was appointed as a director of Bluewater Holdings Corp. in February 2008 until November 2010. In October 2010, the company filed for Chapter 11 bankruptcy and was dissolved thereafter.

Dr Barber was appointed as a director of Segetis Inc. in July 2012 and resigned as director in February 2016. In October 2015, the company was placed into creditors' voluntary liquidation and its assets were sold in early 2016.

Ends

 

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

 

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Adam James / Fabien Holler (Corporate Finance)

Charles Leigh-Pemberton (Corporate Broking)

The information communicated in this announcement is inside information for the purposes of Article 7 of Market Abuse Regulation 596/2014 ("MAR").

 

About Revolymer

Revolymer is an AIM quoted company (registered number 08024489) whose vision is to be a specialty chemicals business focused on controlled release, responsive systems and delivery systems based on its expertise in the design and synthesis of polymers that improve the functional performance of its customers' products, thereby generating high margin business.

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUOORRNSAKAAR
Date   Source Headline
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.